T1	PROC 46 80	Estudio de eficacia y de seguridad
T2	DISO 135 167	carcinoma epidermoide de esófago
#1	AnnotatorNotes T2	C0279626; Squamous cell carcinoma of esophagus; Neoplastic Process
T3	PROC 211 238	Estudio fase Ib/II, abierto
T4	CHEM 289 295	taxano
#2	AnnotatorNotes T4	C0796419; Taxanes; Organic Chemical
T5	CHEM 298 308	Irinotecan
#3	AnnotatorNotes T5	C0123931; irinotecan; Organic Chemical · Pharmacologic Substance
T6	DISO 326 358	carcinoma epidermoide de esófago
#4	AnnotatorNotes T6	C0279626; Squamous cell carcinoma of esophagus; Neoplastic Process
T7	DISO 403 420	cáncer de esófago
#5	AnnotatorNotes T7	C0152018; Esophageal carcinoma; Neoplastic Process | C0546837; Malignant neoplasm of esophagus; Neoplastic Process
T8	DISO 447 489	carcinoma de células escamosas del esófago
T9	PROC 372 379	tratado
#6	AnnotatorNotes T9	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T10	ANAT 482 489	esófago
#7	AnnotatorNotes T10	C0014876; Esophagus; Body Part, Organ, or Organ Component | C1278919; Entire esophagus; Body Part, Organ, or Organ Component
T11	DISO 518 558	Carcinoma esofágico de células escamosas
#8	AnnotatorNotes T11	C0279626; Squamous cell carcinoma of esophagus; Neoplastic Process
T12	PROC 813 831	quimioradioterapia
T13	PROC 675 682	terapia
#9	AnnotatorNotes T13	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T14	CHEM 693 700	platino
#10	AnnotatorNotes T14	C0032207; platinum; Element, Ion, or Isotope
T15	PROC 779 792	quimioterapia
#11	AnnotatorNotes T15	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T16	CHEM 803 810	platino
#12	AnnotatorNotes T16	C0032207; platinum; Element, Ion, or Isotope
T17	DISO 840 861	enfermedad localizada
#13	AnnotatorNotes T17	C0277565; Local disease; Disease or Syndrome
T18	DISO 864 882	Enfermedad medible
#14	AnnotatorNotes T18	C1513041; Measurable Disease; Disease or Syndrome
T19	DISO 938 968	Afectación metastásica del SNC
T20	ANAT 965 968	SNC
#15	AnnotatorNotes T20	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T21	PROC 971 982	Tratamiento
#16	AnnotatorNotes T21	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T22	CHEM 997 1029	anticuerpo antidiana contra HER3
T23	CHEM 1035 1052	inhibidor de PI3K
#17	AnnotatorNotes T23	C1519050; PI3K inhibitors; Organic Chemical · Pharmacologic Substance
T24	ANAT 160 167	esófago
#18	AnnotatorNotes T24	C0014876; Esophagus; Body Part, Organ, or Organ Component | C1278919; Entire esophagus; Body Part, Organ, or Organ Component
T25	ANAT 351 358	esófago
#19	AnnotatorNotes T25	C0014876; Esophagus; Body Part, Organ, or Organ Component | C1278919; Entire esophagus; Body Part, Organ, or Organ Component
T26	ANAT 413 420	esófago
#20	AnnotatorNotes T26	C0014876; Esophagus; Body Part, Organ, or Organ Component | C1278919; Entire esophagus; Body Part, Organ, or Organ Component
T27	ANAT 460 477	células escamosas
#21	AnnotatorNotes T27	C0221910; Squamous Epithelial Cells; Cell
T28	ANAT 528 537	esofágico
#22	AnnotatorNotes T28	C0014876; Esophagus; Body Part, Organ, or Organ Component | C1278919; Entire esophagus; Body Part, Organ, or Organ Component
T29	ANAT 541 558	células escamosas
#23	AnnotatorNotes T29	C0221910; Squamous Epithelial Cells; Cell
T30	DISO 572 583	metastásico
#24	AnnotatorNotes T30	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T31	PROC 599 623	régimen de quimioterapia
T32	DISO 727 738	metastásico
#25	AnnotatorNotes T32	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T33	CHEM 102 108	LJM716
#26	AnnotatorNotes T33	C4507303; LJM716; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T34	CHEM 111 117	BYL719
#27	AnnotatorNotes T34	C2986399; BYL719; Organic Chemical · Pharmacologic Substance
T35	CHEM 242 248	LJM716
#28	AnnotatorNotes T35	C4507303; LJM716; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T36	CHEM 268 274	BYL719
#29	AnnotatorNotes T36	C2986399; BYL719; Organic Chemical · Pharmacologic Substance
T37	PROC 181 188	tratado
#30	AnnotatorNotes T37	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T38	Date 13 17	2012
T39	LIVB 121 130	pacientes
#31	AnnotatorNotes T39	C0030705; Patients; Patient or Disabled Group
T40	LIVB 312 321	pacientes
#32	AnnotatorNotes T40	C0030705; Patients; Patient or Disabled Group
T41	Neg_cue 586 588	No
T42	Duration 764 775	los 6 meses
T43	ANAT 145 156	epidermoide
#33	AnnotatorNotes T43	C0221910; Squamous Epithelial Cells; Cell
T44	ANAT 336 347	epidermoide
#34	AnnotatorNotes T44	C0221910; Squamous Epithelial Cells; Cell
T45	Observation 742 753	recurrencia
#35	AnnotatorNotes T45	C2825055; Recurrence (disease attribute); Pathologic Function
A1	Assertion T31 Negated
A2	Status T37 History_of
A3	Status T9 History_of
A4	Status T31 History_of
A5	Status T21 History_of
A6	Status T22 History_of
A7	Status T23 History_of
#36	AnnotatorNotes T1	C0511730; Identify product efficacy and safety issues; Health Care Activity
#37	AnnotatorNotes T8	C0279626; Squamous cell carcinoma of esophagus; Neoplastic Process
#38	AnnotatorNotes T31	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
#39	AnnotatorNotes T12	C0436307; Chemoradiotherapy; Therapeutic or Preventive Procedure 
#40	AnnotatorNotes T19	C0686377; CNS metastases; Neoplastic Process
R1	Location_of Arg1:T26 Arg2:T7	
R2	Location_of Arg1:T43 Arg2:T2	
R3	Location_of Arg1:T24 Arg2:T2	
R4	Combined_with Arg1:T33 Arg2:T34	
R5	Experiences Arg1:T39 Arg2:T33	
R6	Experiences Arg1:T39 Arg2:T2	
R7	Experiences Arg1:T39 Arg2:T37	
R8	Before Arg1:T37 Arg2:T33	
R9	Combined_with Arg1:T35 Arg2:T36	
R10	Experiences Arg1:T40 Arg2:T35	
R11	Experiences Arg1:T40 Arg2:T4	
R12	Experiences Arg1:T40 Arg2:T5	
R13	Location_of Arg1:T44 Arg2:T6	
R14	Location_of Arg1:T25 Arg2:T6	
R15	Before Arg1:T9 Arg2:T35	
R16	Before Arg1:T9 Arg2:T4	
R17	Experiences Arg1:T40 Arg2:T9	
R18	Experiences Arg1:T40 Arg2:T6	
R19	Before Arg1:T9 Arg2:T5	
R20	Location_of Arg1:T27 Arg2:T8	
R21	Location_of Arg1:T10 Arg2:T8	
R22	Location_of Arg1:T28 Arg2:T11	
R23	Location_of Arg1:T29 Arg2:T11	
R24	Before Arg1:T11 Arg2:T30	
T46	Observation 559 569	recurrente
#41	AnnotatorNotes T46	C0679254; Disease recurrence; Finding
R25	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T46	
T47	Observation 714 724	recurrente
R26	Overlap Arg1:T45 Arg2:T42	
T48	Quantifier_or_Qualifier 589 598	más de un
A8	Assertion T48 Negated
R27	Negation Arg1:T41 Arg2:T48	
R28	Has_Quantifier_or_Qualifier Arg1:T31 Arg2:T48	
R29	Negation Arg1:T41 Arg2:T31	
T49	Observation 643 653	Progresión
#42	AnnotatorNotes T49	C0679254; Disease recurrence; Finding
R30	Overlap Arg1:T49 Arg2:T13	
R31	After Arg1:T49 Arg2:T13	
R32	Used_for Arg1:T14 Arg2:T13	
R33	Overlap Arg1:T13 Arg2:T47	
#43	AnnotatorNotes T47	C0679254; Disease recurrence; Finding
R34	Overlap Arg1:T13 Arg2:T32	
R35	Overlap Arg1:T13 Arg2:T45	
R37	Used_for Arg1:T16 Arg2:T15	
R38	Has_Duration_or_Interval Arg1:T12 Arg2:T42	
R39	Before Arg1:T17 Arg2:T45	
R40	Before Arg1:T17 Arg2:T49	
R41	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T47	
T50	CONC 893 899	RECIST
#44	AnnotatorNotes T50	C4086827; Response Evaluation Criteria in Solid Tumors Version 1.1; Intellectual Product
R42	Location_of Arg1:T20 Arg2:T19	
R43	Used_for Arg1:T22 Arg2:T21	
R44	Used_for Arg1:T23 Arg2:T21	
R45	Before Arg1:T37 Arg2:T34	
R46	Before Arg1:T9 Arg2:T36	
R47	Has_Duration_or_Interval Arg1:T16 Arg2:T42	
A9	Experiencer T39 Patient
A10	Experiencer T40 Patient
